

This week in therapeutics

Indication	Target/marker/athway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myeloid leukemia (CML)	Glycogen synthase kinase 3 β (GSK3 β)	<p>Studies in cell culture and in xenograft mice suggest that increasing GSK3β activity could help treat CML. Human CML progenitor cells transplanted into mice showed lower GSK3β levels than healthy hematopoietic stem cell (HSC) transplants. CML cell lines with mutations in GSK3β that caused incorrect splicing of the protein led to higher levels of leukemic engraftment than those seen in CML cell lines expressing wild-type GSK3β. Next steps include developing diagnostics to detect incorrect splicing of GSK3β as a predictor of disease outcomes and developing methods to increase GSK3β activity in CML cells.</p> <p>SciBX 2(9); doi:10.1038/scibx.2009.353 Published online March 5, 2009</p>	Patent and licensing status undisclosed	<p>Abrahamsson, A.E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 16, 2009; doi:10.1073/pnas.0900189106 Contact: Catriona H.M. Jamieson, University of California San Diego, La Jolla, Calif. e-mail: cjamieson@ucsd.edu</p>